BioSyent Inc. (CVE:RX – Get Rating) – Equities researchers at Bloom Burton cut their FY2022 earnings per share (EPS) estimates for shares of BioSyent in a report released on Thursday, November 17th. Bloom Burton analyst D. Martin now anticipates that the company will post earnings of $0.43 per share for the year, down from their previous forecast of $0.47. The consensus estimate for BioSyent’s current full-year earnings is $0.53 per share. Bloom Burton also issued estimates for BioSyent’s Q4 2022 earnings at $0.10 EPS.
BioSyent Trading Up 1.1 %
Shares of RX opened at C$7.33 on Monday. The stock has a fifty day moving average of C$7.43 and a two-hundred day moving average of C$7.85. The company has a debt-to-equity ratio of 4.52, a quick ratio of 8.38 and a current ratio of 9.29. The company has a market capitalization of C$88.77 million and a PE ratio of 14.66. BioSyent has a fifty-two week low of C$6.24 and a fifty-two week high of C$10.00.
BioSyent Company Profile
BioSyent Inc, a specialty pharmaceutical company, sources, acquires or in-licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX 150, an oral hematinic; FeraMAX Powder, a water soluble oral iron supplement, which helps the body form red blood cells; and FeraMAX Pd Therapeutic 150 for the prevention and treatment of iron deficiency anemia.
- Warren Buffet Bought Taiwan Semiconductor Stock, Should You?
- MarketBeat: Week in Review 11/14 – 11/18
- Target’s Double Bottom Might Have Just Been Confirmed
- How High Can the Fed Go? How to Trade it
- Verra Mobility Stock Has Returned Back to the Station
Receive News & Ratings for BioSyent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSyent and related companies with MarketBeat.com's FREE daily email newsletter.